Latest

After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆ After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA ◆ The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories ◆ Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors ◆ Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows ◆ Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips ◆ Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare ◆

Search Results

Found 2 results for "italy" across articles, medicines, trials, companies and the glossary

The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector

The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector

An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.

How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning

Regulatory Affairs

How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning

An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.